Agenus (AGEN)
Agenus R&D Expense: 2.677M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AGEN R&D Expense Rankings
| Overall | 56th percentile | 770 of 1764 |
| Sector | 67th percentile | 133 of 413 in Healthcare |
| Industry | 73rd percentile | 40 of 150 in Biotechnology |
AGEN R&D Expense Range, Past 5 Years
| Minimum | 2.528M | Sep 2011 |
| Maximum | 6.133M | Sep 2007 |
| Average | 3.998M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these AGEN related companies
AGEN News
@johnkelly $AGEN is not a stock that I follow. Don't know much about it. Sorry.
about 19 days ago by abubnic
about 19 days ago by abubnic
Agenus Reports First Quarter 2012 Financial Results and Corporate Updates
Apr 25, 7:00AM GlobeNewswire
Apr 25, 7:00AM GlobeNewswire
@ikabro $AGEN Had this stock a year ago at $1, but sold it and broke even. Just looked and it is around $6+. In same space as IMUC.
about 39 days ago by FRANKNJ
about 39 days ago by FRANKNJ
$AGEN besides, we aso have a MACD divergence and volume that might confirm a bearish movement
about 39 days ago by nobr3ga
about 39 days ago by nobr3ga
$AGEN the channel that is in might be to steep and unhealthy. H&S formation in place shall put it back in a healthy trendline (Jan-Mar lows)
about 39 days ago by nobr3ga
about 39 days ago by nobr3ga
New Phase 2 Data From Brain Cancer Study With Agenus' Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS
Apr 17, 10:30AM GlobeNewswire
Apr 17, 10:30AM GlobeNewswire
$TARO shareholders sign this online petition if u agree..will be sent to Taro BOD $TEVA $PFE $NVIV $NVS $AGEN $PRGO http://stks.co/3L8b
about 44 days ago by imhobutdydd
about 44 days ago by imhobutdydd
$AGEN this is a beauty in the bank ola. I love hot stocks at the 500,000 volume level.
about 44 days ago by dudedrevon
about 44 days ago by dudedrevon
Cramer hyped $THLD , $AGEN one hype from CRAMER and it gets a volume boost and this baby takes off again
about 46 days ago by dudedrevon
about 46 days ago by dudedrevon
Agenus Reports Fourth Quarter and Year End 2011 Financial Results and Corporate Updates
Mar 05, 8:30AM GlobeNewswire
Mar 05, 8:30AM GlobeNewswire
Agenus to Report Fourth Quarter and Year-End 2011 Financial Results on March 5, 2012; Conference Call to Follow
Feb 29, 10:00AM GlobeNewswire
Feb 29, 10:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AGEN | 5.20 | +0.06 | +1.17% | 116.95M |
| AFCE | 21.69 | +0.84 | +4.03% | 528.80M |
| AFB | 15.39 | +0.04 | +0.26% | |
| AFAM | 21.88 | +0.97 | +4.64% | 205.02M |
| AF | 9.05 | +0.10 | +1.12% | 891.79M |
| AEZS | 0.47 | -0.03 | -5.05% | 49.71M |
| AEY | 2.201 | -0.02 | -0.86% | 22.47M |
| AETI | 4.48 | -0.04 | -0.89% | 35.08M |
| AET | 41.20 | +0.07 | +0.17% | 14.44B |
| AES | 12.55 | +0.17 | +1.37% | 9.629B |
